MarketPulse

Alpha-Thalassemia

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Alpha Thalassemia Market Set for Robust Growth Through 2036 on Gene Therapy Advances

Alpha thalassemia market poised for significant expansion driven by rising prevalence, diagnostic advances, and pipeline therapies from $AGIOS and $NVO through 2036.
BMYCELGrNVOAGIOclinical trialsgene therapy
BenzingaBenzinga··Vandana Singh

Bristol-Myers Squibb Reports Positive Phase 2 Results for Reblozyl in Alpha-Thalassemia

Bristol-Myers Squibb's Reblozyl achieved positive Phase 2 results for Alpha-Thalassemia, showing improved hemoglobin levels and reduced transfusion needs in patients.
BMYCELGrclinical trialdrug development